Seattle Genetics, Inc.

Seagen Inc.

Dana Kennedy

Eric Sievers

Michael Sun

Nathan Ihle

Eric Feldman

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5. 

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents.

Combination of CD33 antibody drug conjugates with chemotherapeutic agents

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A&#x2212; is a Stretcher unit, and p is from about 3 to about 5. 

Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates

Methods for the retreatment of CD30-expressing lymphomas with an anti-CD30 vc-PAB-MMAE antibody-drug conjugate are provided.

Growing community of inventors

Bothell, WA, United States of America

Dana Kennedy